Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel Free EDT Stock Alerts

Spectral Medical (EDT) Competitors

Spectral Medical logo
C$1.33 -0.01 (-0.75%)
As of 07/3/2026 03:51 PM Eastern
Compare

EDT vs. AKU, GEN, LMD, LXG, and SQD

Should you buy Spectral Medical stock or one of its competitors? MarketBeat compares Spectral Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spectral Medical include Akumin (AKU), GeneNews (GEN), LED Medical Diagnostics (LMD), LexaGene (LXG), and SQI Diagnostics (SQD). These companies are all part of the "diagnostics & research" industry.

How does Spectral Medical compare to Akumin?

Spectral Medical (TSE:EDT) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Spectral Medical has a net margin of 0.00% compared to Akumin's net margin of -34.67%. Akumin's return on equity of -483.86% beat Spectral Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Spectral MedicalN/A -973.97% -93.22%
Akumin -34.67%-483.86%0.47%

0.0% of Spectral Medical shares are held by institutional investors. Comparatively, 30.3% of Akumin shares are held by institutional investors. 18.2% of Spectral Medical shares are held by insiders. Comparatively, 33.0% of Akumin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Spectral Medical has a beta of 0.822407, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Akumin has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market.

Spectral Medical has higher earnings, but lower revenue than Akumin. Spectral Medical is trading at a lower price-to-earnings ratio than Akumin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spectral MedicalC$2.76M141.34-C$18.68M-C$0.13N/A
AkuminC$737.69M0.00-C$255.80M-C$3.80N/A

In the previous week, Spectral Medical's average media sentiment score of 0.00 equaled Akumin'saverage media sentiment score.

Company Overall Sentiment
Spectral Medical Neutral
Akumin Neutral

Summary

Akumin beats Spectral Medical on 6 of the 10 factors compared between the two stocks.

How does Spectral Medical compare to GeneNews?

Spectral Medical (TSE:EDT) and GeneNews (TSE:GEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

GeneNews' return on equity of 0.00% beat Spectral Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Spectral MedicalN/A -973.97% -93.22%
GeneNews N/A N/A N/A

0.0% of Spectral Medical shares are owned by institutional investors. 18.2% of Spectral Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Spectral Medical's average media sentiment score of 0.00 equaled GeneNews'average media sentiment score.

Company Overall Sentiment
Spectral Medical Neutral
GeneNews Neutral

GeneNews has lower revenue, but higher earnings than Spectral Medical. Spectral Medical is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spectral MedicalC$2.76M141.34-C$18.68M-C$0.13N/A
GeneNewsC$234.59K0.00-C$11.56M-C$0.07N/A

Summary

GeneNews beats Spectral Medical on 5 of the 8 factors compared between the two stocks.

How does Spectral Medical compare to LED Medical Diagnostics?

LED Medical Diagnostics (CVE:LMD) and Spectral Medical (TSE:EDT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

LED Medical Diagnostics' return on equity of 0.00% beat Spectral Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
LED Medical DiagnosticsN/A N/A N/A
Spectral Medical N/A -973.97%-93.22%

LED Medical Diagnostics has higher revenue and earnings than Spectral Medical. LED Medical Diagnostics is trading at a lower price-to-earnings ratio than Spectral Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LED Medical DiagnosticsC$14.96M1.04-C$1.51M-C$0.04N/A
Spectral MedicalC$2.76M141.34-C$18.68M-C$0.13N/A

In the previous week, LED Medical Diagnostics' average media sentiment score of 0.00 equaled Spectral Medical'saverage media sentiment score.

Company Overall Sentiment
LED Medical Diagnostics Neutral
Spectral Medical Neutral

0.0% of Spectral Medical shares are owned by institutional investors. 18.2% of Spectral Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

LED Medical Diagnostics beats Spectral Medical on 5 of the 9 factors compared between the two stocks.

How does Spectral Medical compare to LexaGene?

LexaGene (CVE:LXG) and Spectral Medical (TSE:EDT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, LexaGene's average media sentiment score of 0.00 equaled Spectral Medical'saverage media sentiment score.

Company Overall Sentiment
LexaGene Neutral
Spectral Medical Neutral

LexaGene's return on equity of -339.54% beat Spectral Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
LexaGeneN/A -339.54% -120.21%
Spectral Medical N/A -973.97%-93.22%

0.1% of LexaGene shares are owned by institutional investors. Comparatively, 0.0% of Spectral Medical shares are owned by institutional investors. 17.9% of LexaGene shares are owned by insiders. Comparatively, 18.2% of Spectral Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LexaGene has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market. Comparatively, Spectral Medical has a beta of 0.822407, indicating that its share price is 18% less volatile than the broader market.

LexaGene has higher earnings, but lower revenue than Spectral Medical. Spectral Medical is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LexaGeneC$110.93K133.13-C$8.54M-C$0.08N/A
Spectral MedicalC$2.76M141.34-C$18.68M-C$0.13N/A

Summary

LexaGene beats Spectral Medical on 6 of the 10 factors compared between the two stocks.

How does Spectral Medical compare to SQI Diagnostics?

SQI Diagnostics (CVE:SQD) and Spectral Medical (TSE:EDT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

25.2% of SQI Diagnostics shares are owned by institutional investors. Comparatively, 0.0% of Spectral Medical shares are owned by institutional investors. 50.2% of SQI Diagnostics shares are owned by insiders. Comparatively, 18.2% of Spectral Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SQI Diagnostics has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market. Comparatively, Spectral Medical has a beta of 0.822407, suggesting that its stock price is 18% less volatile than the broader market.

In the previous week, SQI Diagnostics' average media sentiment score of 0.00 equaled Spectral Medical'saverage media sentiment score.

Company Overall Sentiment
SQI Diagnostics Neutral
Spectral Medical Neutral

SQI Diagnostics' return on equity of 0.00% beat Spectral Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
SQI DiagnosticsN/A N/A -74.70%
Spectral Medical N/A -973.97%-93.22%

Spectral Medical has lower revenue, but higher earnings than SQI Diagnostics. Spectral Medical is trading at a lower price-to-earnings ratio than SQI Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQI DiagnosticsC$3.04M2.01-C$19.14M-C$0.05N/A
Spectral MedicalC$2.76M141.34-C$18.68M-C$0.13N/A

Summary

SQI Diagnostics beats Spectral Medical on 7 of the 10 factors compared between the two stocks.

Get Spectral Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDT vs. The Competition

Export
MetricSpectral MedicalDiagnostics & Research IndustryMedical SectorTSE Exchange
Market CapC$393.18MC$653.79MC$7.16BC$13.07B
Dividend Yield1.45%3.37%2.66%6.18%
P/E Ratio-10.2378.5928.0236.51
Price / Sales141.34617.86540.3710.34
Price / Cash82.5011.4249.2682.29
Price / Book-16.633.2610.964.52
Net Income-C$18.68MC$334.07BC$3.57BC$299.09M
7 Day Performance-2.21%2.25%2.12%1.85%
1 Month Performance-3.62%-0.35%5.25%1.71%
1 Year Performance62.20%7.27%33.29%36.40%

Spectral Medical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDT
Spectral Medical
N/AC$1.33
-0.7%		N/A+62.2%C$393.18MC$2.76MN/A29
AKU
Akumin
N/AN/AN/AN/AC$37.20MC$737.69MN/A1,527
GEN
GeneNews
N/AN/AN/AN/AC$25.49MC$234.59KN/A2,700
LMD
LED Medical Diagnostics
N/AC$0.40
+∞		N/A+0.0%C$15.51MC$14.96MN/A46
LXG
LexaGene
N/AC$0.11
-19.2%		N/A+0.0%C$14.77MC$110.93KN/A41

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:EDT) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel